- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02518399
Chronic Heat Therapy for Improving Vascular Health (CHT)
October 24, 2017 updated by: Christopher T Minson, PhD, University of Oregon
Chronic Heat Therapy for Improving Biomarkers of Vascular Health in Young, Healthy, Humans
The purpose of the study is to investigate whether long-term heat therapy (i.e. 8 weeks of hot tub 4-5x per week) improves biomarkers of cardiovascular health in young, healthy, able-bodied individuals.
Although exercise is a potent means of improving cardiovascular health, many patients are unable to exercise effectively, and thus there is high demand for novel therapies to better manage cardiovascular risk in these patients.
If successful, this study will set the groundwork for heat therapy to be used as an alternative treatment in patients who have limited exercise capabilities for the prevention of cardiovascular disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Exercise training is a potent means of improving cardiovascular (CV) risk; however, exercise is challenging for many patient populations.
Passive heat therapy may provide a simple and effective alternative to exercise for improving CV health, and no one has yet studied the physiological benefits of chronic heat exposure in humans.
Heat exposure induces the expression of heat shock proteins, which can have a multitude of beneficial effects on the CV system, many of which are common to exercise training.
In particular, these benefits include upregulation of many cellular pathways associated with improved vascular function, a predominant contributor to CV health.
The goal of the study is to determine the effects of chronic passive heat therapy on vascular function in young, healthy, able-bodied individuals.
The investigators will perform a randomized-controlled trial in which subjects participate in 8 weeks of either heat therapy or thermoneutral water immersion (sham).
Heat therapy will entail 8 weeks of hot water immersion sufficient to raise core temperature >38.5°C for 1h, 4-5 times per week.
Thermoneutral water immersion will entail 8 weeks of immersion in 36°C water for the same duration as heat therapy.
In both subject groups, the investigators will measure various well-established biomarkers of vascular function before and after 8 weeks of heat therapy, including measures of arterial stiffness (arterial compliance, beta-stiffness, and pulse wave velocity), endothelium-dependent dilation (flow-mediated dilation), and intima media thickness.
The investigators will investigate the effects of heat therapy on the microvasculature and on the mechanisms behind improvements in vascular function in the cutaneous microcirculation, an ideal site for pharmacodissecting the molecular pathways involved, using microdialysis paired with laser-Doppler flowmetry.
If successful, these studies will serve as a basis for developing heat therapy as a novel means of improving CV risk, which has the potential to reshape the treatment of patient populations with limited exercise capabilities.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oregon
-
Eugene, Oregon, United States, 97403
- University of Oregon
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Young, healthy, able-bodied
Exclusion Criteria:
- Diagnosis of any chronic diseases related to the cardiovascular system (e.g. hypertension, cardiovascular disease, diabetes, etc.),
- Currently taking prescription medications (except contraceptives)
- Body mass index over 27 kg/m2
- Current smoking
- Currently pregnant or breast-feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Heat therapy
Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions.
In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C
for 60min.
|
Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions.
In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C
for 60min.
|
|
Sham Comparator: Thermoneutral water immersion
Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions.
In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
|
Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions.
In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in flow-mediated dilation
Time Frame: 8 weeks
|
The change in percent dilation of the brachial artery following release of a 5-min arterial occlusion, measured using ultrasonography.
This test is highly prognostic of cardiovascular risk and mortality.
|
8 weeks
|
|
Femoral dynamic arterial compliance
Time Frame: 8 weeks
|
The change in compliance of the superficial femoral artery relative to blood pressure, measured using ultrasonography-tonometry.
This is a measure of arterial stiffness.
|
8 weeks
|
|
Intima media thickness
Time Frame: 8 weeks
|
Change in wall thickness of the common carotid artery, measured using ultrasonography.
This is predictive of future development of cardiovascular disease, in particular, atherosclerosis.
|
8 weeks
|
|
Mean arterial blood pressure
Time Frame: 8 weeks
|
Change in blood pressure measured using brachial oscillation following >20 min supine rest.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cutaneous nitric oxide-dependent dilation
Time Frame: 8 weeks
|
Change in the difference between cutaneous microdialysis sites receiving a nitric oxide inhibitor (L-NNA, IND # 124,303) and Lactated Ringer's (control).
Measured using laser-Doppler flowmetry during a local heating protocol.
|
8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Carotid dynamic arterial compliance
Time Frame: 8 weeks
|
Change in compliance of the common carotid artery relative to blood pressure, measured using ultrasonography-tonometry.
This is a measure of arterial stiffness.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2013
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
April 30, 2016
Study Registration Dates
First Submitted
July 23, 2015
First Submitted That Met QC Criteria
August 4, 2015
First Posted (Estimate)
August 7, 2015
Study Record Updates
Last Update Posted (Actual)
October 26, 2017
Last Update Submitted That Met QC Criteria
October 24, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09272013.025
- 14PRE20380300 (Other Grant/Funding Number: American Heart Association)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Hull University Teaching Hospitals NHS TrustNot yet recruitingCardiovascular Surgery | Cardiovascular Diseases (CVD)United Kingdom
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk FactorsUnited States
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS and other collaboratorsRecruitingCardiovascular Risk | Genetic Cardiovascular RiskItaly
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiovascular Diseases (CVD)United States
Clinical Trials on Heat therapy
-
Tribhuvan University, NepalCompletedLabour Pain | Heat Therapy | Cold TherapyNepal
-
Universidad Peruana Cayetano HerediaTulane University School of MedicineAvailableCutaneous Leishmaniasis
-
Lithuanian Sports UniversityCompleted
-
University of OregonAmerican Heart AssociationCompletedObesity | Polycystic Ovary Syndrome | Metabolic Syndrome | PreDiabetes | Prehypertension | Cardiovascular Risk FactorUnited States
-
Sight Sciences, Inc.Active, not recruitingMeibomian Gland Dysfunction (Disorder)United States
-
University of MinnesotaNot yet recruiting
-
Manchester Metropolitan UniversityBritish Heart FoundationNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Intermittent Claudication | Vascular Function | Cardiovascular HealthUnited Kingdom
-
Indiana UniversityPurdue University; Roseguini, Bruno, PhDWithdrawnPeripheral Arterial Disease
-
The University of Texas Health Science Center at...Congressionally Directed Medical Research ProgramsRecruitingSCI - Spinal Cord InjuryUnited States
-
University of Texas Southwestern Medical CenterCompleted